India's CDSCO Finalizes Medical Device Software Guidance with AI/ML Algorithm Change Protocol
Key Questions
What does India's CDSCO guidance cover for medical device software?
The final guidance formalizes an Algorithm Change Protocol (ACP) for AI/ML software and distinguishes between SiMD and SaMD. It provides a clear regulatory pathway aligned with FDA and EU approaches.
Why is the CDSCO guidance important for regulatory teams?
It addresses key industry pain points and offers explicit rules for AI algorithm changes in the Indian market. RA/QA teams targeting India will need to follow these new requirements.
How does the Indian guidance relate to international trends?
CDSCO's approach mirrors global developments at the FDA and in the EU regarding AI/ML software oversight. This supports more harmonized regulatory strategies for companies operating across regions.
CDSCO released final guidance on medical device software, formalizing Algorithm Change Protocol (ACP) for AI/ML and explicitly distinguishing SiMD vs SaMD. This aligns with global trends (FDA, EU) and is critical for RA/QA teams targeting the Indian market. The guidance addresses industry pain points and provides a clear regulatory pathway. Confirmed in Asia-Pacific roundup.